Specialty Pharmacy

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Younger cancer survivors and those with high deductible private insurance plans experienced the greatest financial burden.

Top news of the day across the health care landscape.

Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.

An inhaled medication for a disease that does not affect the lungs may prove to be a promising concept in the treatment of chronic diseases.

The new indication would allow treatment-experienced patients with HIV to switch to Pifeltro in combination with other HIV medications or Delstrigo.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.

Top news of the day across the health care landscape

Innovations such as the Apple iPhone HealthKit could help create a smooth transition throughout the patient journey all the way to the specialty pharmacy.

An overview of scientific evidence supporting the HIV undetectable=untransmittable concept and implications for HIV prevention and treatment.

Top news of the day across the health care landscape.

Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.

Top news of the day across the health care landscape.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, gives an overview of the exciting therapeutic developments in the B-cell lymphoma space.

From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.

Officials with the FDA today approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin.

Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.

Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.

The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.

Top news of the day across the health care landscape.

Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.

Vigabatrin, which is also sold under the brand name Sabril, is used to treat complex partial seizures in adult and pediatric patients.